POSTERS SIMPLES

JOUR 1 (PS1) : MERCREDI 12 JUIN

  • PS1-001 - Retention in Opioid Substitution Therapy in Lebanese National Program: Predictors and Determinants - Zeinab ABBAS (Beyrouth)
  • PS1-002 - Non-steroidal anti-inflammatory drugs effect on sport performance in healthy people: a meta-analysis of randomized controlled trials - Catherine CORNU (Lyon)
  • PS1-003 - Clinical impact of four genetic variants of m-TOR in kidney transplant recipients treated with sirolimus - Nicolas PICARD (Limoges)
  • PS1-004 - Implementing a centralized pharmacovigilance service for a phase II, multicenter, ebola vaccine clinical trial in West Africa - Stephany PONG (Paris)
  • PS1-005 - Hepatotoxicity risk factors and acetaminophen dose adjustment, do prescribers give this issue adequate consideration? A French university hospital study - Astrid BACLE (Rennes)
  • PS1-006 - Tianeptine use disorder : literature review - Audrey FRESSE (Nancy)
  • PS1-007 - Intravenous oxycodone does not reduce postoperative adverse event and pain relief compared to morphine: a randomized controlled trial - Jean-Luc FAILLIE (Montpellier)
  • PS1-008 - Modeling of Glomerular filtration rate (GFR) based on the clearance of iohexol in Intensive Care unit patients - Jean-Baptiste WOILLARD (Limoges)
  • PS1-010 - Added value of aortic pulse wave velocity index for the detection of coronary heart disease by elective coronary angiography - Alexandre VALLÉE (Paris)
  • PS1-011 - Stability Study of Cefepime in NaCl at different Storage Times and Temperatures - Alice RESSAULT (Toulouse)
  • PS1-012 - Voriconazole chronic underexposure in a non-extensive metabolizer treated for disseminated Scedosporium prolificans infection: which pharmacological approach to increase voriconazole drug level? - Christelle BOGLIONE-KERRIEN (Rennes)
  • PS1-013 - Impact of pregnancy on antidepressant treatment course: a population-based comparative cohort study in France - Anne BÉNARD-LARIBIÈRE (Bordeaux)
  • PS1-014 - What about cannabidiol in France? - Anne BATISSE (Paris)
  • PS1-015 - Benzodiazepine withdrawal in elderly: what prevalence, what signs, which patients? Clinical National survey of substance use disorder assessment in senior dependent population - Alexandra JOBERT (Nantes)
  • PS1-016 - Seizures of counterfeit drugs and dietary supplements in Paris: a 3 years study - Nicolas FABRESSE (Garches)
  • PS1-017 - The general practitioner’s knowledge and attitude towards proton pump inhibitors adverse effects - Marie-Laure LAROCHE (Limoges)
  • PS1-018 - Population pharmacokinetic analysis and limited sampling strategy of ofloxacin in patients with bone and joint infections - Jean-Baptiste FOULQUIER (Rennes)
  • PS1-019 - Effect of a chronic treatment with an arginase inhibitor on cerebrovascular endothelial dysfunction in Adjuvant-Induced Arthritis - Perle TOTOSON (Besançon)
  • PS1-020 - Simultaneous determination of eight β-lactam antibiotics in human plasma and cerebrospinal fluid by liquid chromatography coupled to tandem mass spectrometry - Ronan BELLOUARD (Nantes)
  • PS1-021 - Medication errors involving Opioid Maintenance Therapy: a French pharmacovigilance database analysis - Hélène PEYRIERE (Montpellier)
  • PS1-022 - Interest and delicate interpretation of hair analysis in mistreatment of hospitalized older people - Jean-Claude ALVAREZ (Garches)
  • PS1-023 - Vitamin D3 supplementation and incidence of antibiotic prescriptions - Jean-Luc FAILLIE (Montpellier)
  • PS1-024 - The 2018 state of the art on the Cardiovascular Risks of Cannabis-Based Products: a systematic review - Emilie JOUANJUS (Toulouse)
  • PS1-025 - Incretin-based drugs and intestinal obstruction: analysis of the World Health Organization’s adverse drug reactions database - Jean-Luc FAILLIE (Montpellier)
  • PS1-026 - Doping behaviours in the amateur sport: a descriptive study among trailers - Emilie JOUANJUS (Toulouse)
  • PS1-027 - Impact of generic drug dispensing practices on the perception of generic drugs and the pharmacist/patient relationship - Emilie JOUANJUS (Toulouse)
  • PS1-028 - Cluster headache in subjects with substance use disorder: a case series and a review of the literature - Camille PONTÉ (Toulouse)
  • PS1-029 - Problematic use of psychoactive substances: elderly are not spared - Marie GERARDIN (Nantes)
  • PS1-030 - Addictovigilance in the youngest: tell me your age, I will tell you what you take - Marylène GUERLAIS (Nantes)
  • PS1-031 - Psychoactive substances use among young people: how to make the invisible visible - Hélène LOMENECH (Nantes)
  • PS1-032 - Appropriate use of drugs in the elderly: Retrolective study in a local Hospital Center in France - Haleh BAGHERI (Toulouse)
  • PS1-033 - The first national study in paediatric dentistry regarding the effects of Equimolar Mixture of Oxygen and Nitrous Oxide (EMONO): MEOPAeDent trial protocol - Tony PRUDHOMME (Nantes)
  • PS1-034 - Compulsive buying and pathological gambling behaviour associated with the use of selective serotonin reuptake inhibitors - Chayma LADHARI (Montpellier)
  • PS1-035 - Vasculitis as an adverse event following vaccination : a descriptive analysis across the French Pharmacovigilance database - Hélène GÉNIAUX (Limoges)
  • PS1-036 - Potential interest of a pharmacometric approach in Poison Control Centre activities: example of a suspicion of morphine overdosing in a newborn - Patrice NONY (Lyon)
  • PS1-037 - Potential interest of the collaboration between an Addictovigilance Centre, an Addictology Department and a Pharmacometry Department : example of zolpidem overdosing in a patient - Patrice NONY (Lyon)
  • PS1-038 - A tool for improve ADRs reports in emergency medical communication center - Julien MAHÉ (Nantes)
  • PS1-039 - Two novel genetic models of major depressive disorders display heterogeneous sensitivity to treatments - Malika EL YACOUBI (Lyon)
  • PS1-040 - Professional practice evaluation on contrast media extravasations in Rennes University Hospital and pharmacovigilance involvement - Sébastien LALANNE (Rennes)
  • PS1-041 - Using binding competitors on albumin to promote the removal of protein-bound uremic toxins in hemodialysis: proof of concept and screening of candidates - Nans FLORENS (Lyon)
  • PS1-042 - Hepatotoxicity induced by antipsychotic agents belonging to the dibenzazepine family: a cumulative toxicity? - Chayma LADHARI (Montpellier)
  • PS1-043 - Adalimumab induced myositis: a new safety signal? - Louise GABORIAU (Lille)
  • PS1-044 - National Patient Safety Program: How to improve knowledge on self-medication? - Mélanie MOLTENIS (Besançon)
  • PS1-045 - Patient safety week : evaluation of the post-approval surveillance system knowledge with patients - Anne-Lise RUELLAN (Nantes)
  • PS1-046 - Impact of sleeve-gastrectomy in patients treated with tyrosine kinase inhibitors in chronic myeloid leukemia: about 2 cases - Louise GABORIAU (Lille)
  • PS1-047 - A proposal for medication errors management in pharmacovigilance - Nadège PARASSOL-GIRARD (Nice)
  • PS1-048 - Partial application of narcotic regulation to medicines available in community pharmacies in France (1992-2018) - Ghada MIREMONT-SALAME (Bordeaux)
  • PS1-049 - Apomorphine: a fatal adverse event with an old drug commonly used - Elise K. VAN OBBERGHEN (Nice)
  • PS1-050 - Do immune checkpoint inhibitors increase risk of NSAID and / or PPI renal toxicity? - Marjorie BERNIER (Nice)
  • PS1-051 - The pharmacokinetics of tranexamic acid through intravenous, intramuscular and oral routes: a meta-analysis of studies in healthy volunteers - Stanislas GRASSIN-DELYLE (Paris)
  • PS1-052 - A case of chemotherapy-induced subacute cutaneous lupus erythematosus - Dominique HILLAIRE-BUYS (Montpellier)
  • PS1-053 - Radiopharmacological exploration of [18F]F13640, a 5-HT1A radiotracer sensitive to brain serotonin fluctuations - Matthieu COLOM (Bron)
  • PS1-054 - ITPA activity in children treated with azathioprine : Relation to adverse events and inflammatory response - Roselyne BOULIEU (Lyon)
  • PS1-055 - Serious health complications related to methylphenidate abuse - Elisabeth FRAUGER (Marseille)
  • PS1-056 - Safety of the use of anti-IL17A treatment in a patient with TNF inhibitor-induced sarcoidosis - Matthieu BEREAU (Besançon)
  • PS1-057 - The PregMed-France Cohort: Prevalence and trend of medication use during pregnancy in the French population - Anick BÉRARD (Lyon)
  • PS1-058 - Typology of existing pharmacokinetic models allowing to link intrathecal doses and intravenous, oral or nasal doses for xenobiotics - Cécile BOULOUET (Lyon)
  • PS1-059 - The impact of weekly visits by a Pharmacovigilance Centre practitioner in an Universitary Hospital Intensive Care Unit on questions and notifications - Laurence LAGARCE (Angers)
  • PS1-060 - Identification of self-medication drugs involved in drug interactions and adverse effects in the French National PharmacoVigilance Database - Laurence LAGARCE (Angers)
  • PS1-061 - Cushing’s syndrome related to interaction between ritonavir or cobicistat and corticosteroid: a French Pharmacovigilance Database study - Paul BESNIER (Caen)
  • PS1-062 - Isoniazid and cocaine: a new combination? - Emilie BOUQUET (Poitiers)
  • PS1-063 - Sinusoidal Obstruction Syndrome (SOS): Warning about Autologous Stem Cell Transplantation (ASCT) Preceded By Regimens Containing Oxaliplatin - Anaïs EL HACHEMI (Pierre-Bénite)
  • PS1-064 - Unexpected serious ocular and neurological immune-related adverse events in a patient treated with the anti-PD-L1 durvalumab - Pascale OLIVIER (Toulouse)
  • PS1-065 - Psoriasis after calcium channel blockers exposure: French Pharmacovigilance data - Aurore MOREL (Reims)
  • PS1-066 - Pharmacokinetic and pharmacodynamic profile of beta-lactam antibiotics in patients treated for infective endocarditis: a five-year retrospective study - Sébastien LALANNE (Rennes)
  • PS1-067 - Beta-lactams and Proton Pump Inhibitors: a new example of renal transporters mediated drug-drug interaction - Sébastien LALANNE (Rennes)
  • PS1-068 - Alpha-adrenergic blocking agents during pregnancy: a case series - Marlène DAMIN-PERNIK (Saint-Priest-En-Jarez)
  • PS1-069 - Infectious Adverse Drug Reactions of Idelalisib: study in the French Pharmacovigilance Database - Ana Maria MONTOYA TORRES (Paris)
  • PS1-070 - Why does clinical trials safety unit send so many queries after a Serious Adverse Event report? - Marylaure GAVARD (La Tronche)
  • PS1-071 - Reporting adverse drug reactions by general practitioners in a University multi-professional primary care structure: influence of medical student involvement - Sandrine COMBRET (Dijon)
  • PS1-072 - Interest of identifying cases of abuse/dependence through a psychiatric hospital database: a pilot study by the Addictovigilance Center at NANCY France - Valérie GIBAJA (Nancy)
  • PS1-073 - Evaluation of the use of Complementary and Alternative Medicine associated with a risk of drugs interactions in cancer patients - Camille SERENI (Saint-Priest En Jarez)
  • PS1-074 - General public knowledge about drugs and their risks : highlighting successful and unsuccessful public health messages - Marina BABIN (Angers)
  • PS1-075 - Pitch perception modification due to carbamazepine - Brendan LE DARE (Rennes)
  • PS1-076 - A case report of mefloquine-induced neuropsychiatric disorders in a 13-month-old child - Dominique HILLAIRE-BUYS (Montpellier)
  • PS1-077 - Strengths and limitations of a large Healthy Volunteers’ Database used for phone pre-recruitment in a clinical study - Stéphanie SOMERS (Lille)
  • PS1-078 - Nivolumab-induced pulmonary arterial hypertension - Jean-Luc FAILLIE (Montpellier)
  • PS1-079 - Consumption of Ayahuasca and antipsychotics: risk factor for priapism - Hélène PEYRIÈRE (Montpellier)
  • PS1-080 - Data and Safety Monitoring Board activity in academic clinical trials: 6-years activity report from establishments of REVISE national group - Sophie DURANTON (Poitiers)
  • PS1-081 - Deferasirox-induced maculopathy - Jean-Luc FAILLIE (Montpellier)
  • PS1-082 - Pembrolizumab induced fatal myositis and myocarditis - Nadine PETITPAIN (Nancy)
  • PS1-083 - Chemical submission to the extremes of life: data in France - Leïla CHAOUACHI (Paris)
  • PS1-084 - Therapeutic Drug Monitoring of methotrexate in patients with glucarpidase rescue - Christelle BOGLIONE-KERRIEN (Rennes)

 

JOUR 2 (PS2) : JEUDI 13 JUIN

  • PS2-001 - Involuntary muscular movements as adverse reactions to sacubitril/valsartan - Theodora BEJAN-ANGOULVANT (Tours)
  • PS2-002 - Clinicians satisfaction survey on pharmacovigilance responses after drug adverse effects declarations and queries in Rennes University Hospital - Louise TRIQUET (Rennes)
  • PS2-003 - Analysis of nivolumab-related cholangitis cases - Marion SASSIER (Caen)
  • PS2-004 - Tako-tsubo cardiomyopathy and cardiogenic shock induced by a discontinuation of ruxolitinib: a case report - Marion SASSIER (Caen)
  • PS2-005 - Anti-D or Intravenous immunoglobulins for immune thrombocytopenia in children: systematic review and meta-analysis - Theodora BEJAN-ANGOULVANT (Tours)
  • PS2-006 - Lidocaine/prilocaine-induced methemoglobinemia: particular risk of inappropriate use in infants - Jean-Luc FAILLIE (Montpellier)
  • PS2-007 - Drug-drug interaction between tramadol and fluconazole - Sophie FEDRIZZI (Caen)
  • PS2-008 - Drug-induced Ogilvie’s syndrom - Nice Jodie KAKANAKOU (Saint-Priest-En-Jarez)
  • PS2-009 - Analysis of clinical trials queries issued by vigilance department of Poitiers university hospital - Sophie DURANTON (Poitiers)
  • PS2-010 - Immune reconstitution inflammatory syndrome: a side effect of IL-7? - Sophie FEDRIZZI (Caen)
  • PS2-011 - Emergence of the use of Kratom (Mitragyna speciosa) linked to serious adverse events - Reynald LE BOISSELIER (Caen)
  • PS2-012 - Inhaled Butane-Isobutane-Propane and acute intoxication: a case report - Reynald LE BOISSELIER (Caen)
  • PS2-013 - Fatal intoxication with Kratom : a case report - Joanna BOURGINE (Caen)
  • PS2-014 - Comparison of LC-MS and turbidity methods to analyse teicoplanine in plasma samples - Sarah BAKLOUTI (Toulouse)
  • PS2-015 - Does defibrotide still have secrets? - Delphine CALLOT (Paris)
  • PS2-016 - Will flecainide help us to forget Mediator®? - François GUEYFFIER (Lyon)
  • PS2-017 - Validation of an ultrahigh performance liquid chromatography-tandem mass spectrometry method for the quantification of cyclosporine in endomyocardial biopsies - Camille TRON (Rennes)
  • PS2-018 - Cardiovascular adverse drug reactions of ibrutinib, idelalisib, acalabrutinib and venetoclax used in chronic lymphocytic leukemia: Signal detection by disproportionality analysis from VigiBase® - Tatiana PACHECO-PÁEZ (Toulouse)
  • PS2-019 - Methadone poisonings: a seven year retrospective study of the French Poison Centers Network focusing on suicide attempts versus misuses - Romain TORRENTS (Marseille)
  • PS2-020 - Pediatric inpatient medication errors belonging to the French “Never Events” list - Thibault DE WITASSE-THEZY (Paris)
  • PS2-021 - Pharmacokinetics and Pharmacogenetics of clozapine in Tunisians schizophrenic patients - Haifa BEN ROMDHANE (Monastir)
  • PS2-022 - Neurological adverse effects related to linezolid : review of the French Pharmacovigilance Database (FPVD) - Thibault DE WITASSE-THEZY (Paris)
  • PS2-023 - Effect of selective serotonin reuptake inhibitors on bone mineral density: a re-analyzed meta-analysis - Charles KHOURI (Grenoble)
  • PS2-024 - Population Pharmacokinetic of Tacrolimus in Tunisian Renal Transplant Patients: Influence of CYP34A and CYP3A5 Polymorphisms - Haifa BEN-ROMADHANE (Monastir)
  • PS2-025 - Influence of Combined CYP3A4/CYP3A5 Polymorphisms on Tacrolimus Pharmacokinetic in Tunisian Renal Graft Patients - Haifa BEN-ROMADHANE (Monastir)
  • PS2-026 - Evaluation of the antidepressant effect of chronic administration of Nigella fixed oil versus fluoxetine in rats - Youness KADIL (Casablanca)
  • PS2-027 - Assessment of time spent for Clinical trial vigilance activities in an academic Trials Vigilance Unit - Catherine MOUCHEL (Rennes)
  • PS2-028 - Limited Sampling Strategy of Isoniazid in Tunisian tuberculosis patients - Haifa BEN ROMDHANE (Monatir)
  • PS2-029 - Profile of plasmatic concentrations and adverse effects of efavirenz and tenofovir in HIV patients in Benin - Aurel Constant ALLABI (Abomey Calavi)
  • PS2-030 - Is the current contra-indication of nefopam in epilepsy warranted? - Béatrice SAINT-SALVI (St Denis)
  • PS2-031 - Neonatal complications following psychotropic drugs use during pregnancy: Retrospective study in two maternity hospital - Chayma LADHARI (Montpellier)
  • PS2-032 - Overview of synthetic and biologic disease-modifying antirheumatic drugs use during pregnancy - Chayma LADHARI (Montpellier)
  • PS2-033 - Can we extrapolate the results of trials evaluating reduced-dose of DOACs to the French population? Data from the CACAO study - Laurent BERTOLETTI (Saint-Etienne)
  • PS2-034 - Pharmacovigilance in radiopharmaceuticals : factors causing altered images in nuclear medicine - Sarah LANGLET (Montpellier)
  • PS2-035 - Cannabidiol is bad for you! - Michel MALLARET (Grenoble)
  • PS2-036 - Nefopam-induced Urinary urgency: a case-report - Paul BESNIER (Caen)
  • PS2-037 - FAK inhibits invasion potential in advanced or metastatic melanoma cells - Antoine MOUSSON (Strasbourg)
  • PS2-038 - Characterization of an endothelial-mesenchymal transition cell model - application to melanoma - Valentin PLATEL (Angers)
  • PS2-039 - Safety of BRAF and MEK inhibitors for treatment of metastatic melanoma: disproportionality analysis in Vigibase - Ghada MIREMONT-SALAMÉ (Bordeaux)
  • PS2-040 - Lithium poisoning after overexposure for 1 month: about two avoidable accidents - Marie ROUAULT (Le Petit-Quevilly)
  • PS2-041 - Acute confusion with aphasia caused by encephalopathy under trametinib monotherapy - Mylène TISSEYRE (Paris)
  • PS2-042 - Medication errors with oral chemotherapies: highlights from cases reported in the French Pharmacovigilance Database - Mylène TISSEYRE (Paris)
  • PS2-043 - PPAR-ƴ gene rs1801282 association with therapeutic response after antidepressant treatment in depressed patients - Céline VERSTUYFT (Paris)
  • PS2-044 - Use of the PMSI database: analysis of the adverse drug reactions coded in Caen University Hospital in 2017 - Sophie FEDRIZZI (Caen)
  • PS2-045 - Torsadogenic potential of citalopram and hydroxyzine: how psychiatrists should manage their use for the patients' benefit - Béatrice SAINT-SALVI (St Denis)
  • PS2-046 - Gender impact on adverse drug reactions occurence in patients with statins in general medicine - Xavier HUMBERT (Caen)
  • PS2-047 - Overview of clinical trials vigilance units in French academic sponsors (REVISE group) - Nadine PETITPAIN (Nancy)
  • PS2-048 - Drug induced extremity vasoconstriction (except Raynaud phenomenon): data from the French PharmacoVigilance Database - Louise GABORIAU (Lille)
  • PS2-049 - SOD2 genetic polymorphism (rs4880) has no impact on 6-month response to antidepressant treatment and inflammatory biomarkers in depressed patients - Céline VERSTUYFT (Le Kremlin-Bicêtre)
  • PS2-050 - Effectiveness of pharmaceutical interventions: comparison between two levels of analysis in a geriatric department - Mickaël BERTHO (Rouen)
  • PS2-051 - Acetaminophen overdose: description and management - Caroline JOYAU (Nantes)
  • PS2-052 - Nivolumab induced lichen planus - Frank ROUBY (Marseille)
  • PS2-053 - Clinical evaluation of Medical Devices: proposition for a strategy based on decision trees - Aurélie PORTEFAIX (Villeurbanne)
  • PS2-054 - Assessment of adverse effects of antipsychotic drugs in the French pharmacovigilance database and associated risk factors - Cécile PAGEOT (Bordeaux)
  • PS2-055 - Effectiveness of human intravenous immunoglobulin on toxic shock syndrome: a pediatric pilot study - Aurélie PORTEFAIX (Lyon)
  • PS2-056 - Assessment of adverse drug reaction related to antidepressant registered in the French pharmacovigilance database - Amandine GOUVERNEUR (Bordeaux)
  • PS2-057 - Assessment of adverse drug reaction related to benzodiazepines and related drugs registered in the French pharmacovigilance database - Amandine GOUVERNEUR (Bordeaux)
  • PS2-058 - Quantitative and qualitative evaluations of data of serious adverse events reported to the vigilance unit during clinical trials - Dunya AYDIN (Lyon)
  • PS2-059 - Benefits of the new oral tablet formulation on posaconazole exposure in cystic fibrosis patients - Céline MORY (Rouen)
  • PS2-060 - benzofuries among the New Psychoactive Substances : a warning about cardiovascular risk - Reynald LE BOISSELIER (Caen)
  • PS2-061 - Sex and gender interaction in randomized controlled trials: a meta-epidemiological approach - Roubi KILO (Lyon)
  • PS2-062 - One year of Never Events in Hauts-De-France Region, France - Isabelle CARPENTIER (Lille)
  • PS2-063 - The clinical and epidemiological aspects of toxidermia: Experience of the Tunisian National Centre of Pharmacovigilance - Fatma BEN SALEM (Tunis)
  • PS2-064 - A case associating a photosensitivity reaction and exacerbation of a pre-existing psoriasis induced by oral terbinafine - Riadh DAGHFOUS (Tunis)
  • PS2-065 - Atypical adverse drug reactions involving bradykinin - Sandrine BERGERON (Lille)
  • PS2-066 - Atypical side effect of mefloquine: a naevi eruption - Fatma BEN SALEM (Tunis)
  • PS2-067 - Intermittent preventive treatment during pregnancy; assessment of prescription and compliance in 183 pregnant women in the Health Region of Abidjan 2 and their evolutions (2008/2016) - Jean-Claude YAVO (Abidjan)
  • PS2-068 - Antidepressant plants with serotonergic mechanism - Fatima GHRMIRED (La Nouvelle Ville Ali Mendjeli)
  • PS2-069 - In silico model of platelet membrane-drug interaction: a promising new tool in pharmacology - Jennifer LAGOUTTE-RENOSI (Besançon)
  • PS2-070 - Assessment of voriconazole trough concentration when coadministrated with corticosteroids - Riadh DAGHFOUS (Tunis)
  • PS2-071 - Visualization of the ticagrelor’s impact on the platelet plasma membrane lipid order by a fluorescent probe - Jennifer LAGOUTTE-RENOSI (Besançon)
  • PS2-072 - Proposal of isoniazid initial dosage in Tunisian tubeculosis patients - Haifa BEN ROMDHANE (Monastir)
  • PS2-073 - Development of Population pharmacokinetics Model of continuous infusion of Vancomycin - Haifa BEN ROMDHANE (Monastir)
  • PS2-074 - French teenagers, young adults and purple drank - Sylvie DEHEUL (Lille)
  • PS2-075 - Use of cannabis extracts sold in internet for child epilepsy: a case report in France - Juliana TOURNEBIZE (Nancy)
  • PS2-076 - Implication of endothelin-1 in human aortic valve calcification - Bérénice COLLEVILLE (Rouen)
  • PS2-077 - Ezh2 as an epigenetic checkpoint during monocyte differentiation: a potential target for cardiac recovery after myocardial infarction - Julie RONDEAUX (Rouen)
  • PS2-078 - Effects of pharmacological inhibition of the hydrolase activity of soluble epoxide hydrolase in a rat model of pulmonary hypertension associated with cardiac insufficiency - Matthieu LEUILLIER (Rouen)
  • PS2-079 - Misoprostol and congenital malformations: a meta-analysis of etiologic observational studies - Judith COTTIN (Lyon)
  • PS2-080 - Benzodiazepines and risk of autonomy loss for Activities of Daily Living in the elderly - Antoine PARIENTE (Bordeaux)
  • PS2-081 - Buprenorphine poisoning: a 10 years experience of Marseille Poison Control Center - Katharina VON FABECK (Marseille)
  • PS2-082 - Antiemetic treatment for chemotherapy-induced nausea and vomiting: patients', oncologists' and nurses' perspectives - Martin DURACINSKY (Le Kremlin-Bicêtre)
  • PS2-083 - Are hospitalized children more at risk of experiencing serious health outcomes, a systematic review - Elham JABERI (Lyon)
  • PS2-084 - Drug-related questions from general practitioners submitted to a French Regional Pharmacovigilance Centre - Geneviève DURRIEU (Toulouse)
  • PS2-085 - A 5 months case of sudden infant death syndrome (SIDS) associated with beta-blocker for hemangioma - Antoine COQUEREL (Caen)

Copyright © key4events - All rights reserved